Phase 2: testing Dupilumab for Pruritis
The goal of this study is to test the how well it works of Dupixent in improving post-burn itching symptoms versus the current standard of care.
Official registry: https://clinicaltrials.gov/study/NCT06226610 · Akron Children's Hospital · enrollment listed as 46
What this phase means
Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Dupilumab, or Placebo. The registry lists allocation as randomized. The goal of this study is to test the how well it works of Dupixent in improving post-burn itching symptoms versus the current standard of care.
They plan to enroll about 46 people at Akron. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy of Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
Interventions: Dupilumab, Placebo
Primary outcome (registry wording): Itch Severity Scale (ISS) Scores
Who it is for (from inclusion criteria)
- Ages 18 Years to 60 Years
Who the registry excludes
- Currently taking Dupixent for any other diagnosis
- known allergy to Dupixent
- pregnant and or lactating mothers
- anyone treated for pruritus using laser therapy
- currently receiving adequate relief for pruritis under standard of care medical management by antihistamine or neuroleptic medications
- Currently taking steroids
- persons with developmental delays or otherwise unable to complete measures
Public study contact (from the registry)
ANJAY KHANDELWAL, MD
akhandelwal@akronchildrens.org
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- Akron Children's Hospital — Akron, Ohio (recruiting)
FAQ about this NCT record
Is NCT06226610 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT06226610?
Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT06226610?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary